高清不卡日本v二区在线,天天综合网天天综合,激情丁香五月天婷婷水蜜桃视频,91精品免费久久久久久久久,手机看片久久久久久久久,日日夜夜嫩草,日本不卡 在线视频,欧美亚洲日韩,高潮歹无毛免费观看视频,天天综合网7799日日夜夜永,欧美日本国产日韩激情视频 ,久久久无码精品亚洲日韩蜜桃,日夜夜天天人人综合网,91蜜桃长长久久,国产精品精品一区在线发布,一级a毛片免费观看久久精品

In the United States, the primary regulatory authorities for Clinical Trial Reports are:

1. Food and Drug Administration (FDA)

• Role: The FDA is the main regulatory body overseeing clinical trials for drugs, biologics, and medical devices. It reviews Clinical Trial Reports as part of the New Drug Application (NDA), Biologics License Application (BLA), or Premarket Approval (PMA) process.
• Website: FDA

2. Institutional Review Boards (IRBs)

• Role: IRBs review and approve clinical trial protocols and ensure that trials are conducted ethically and that participants' rights are protected. They are not regulatory bodies but play a crucial role in the oversight of clinical trials.
• Website: Office for Human Research Protections (OHRP)

3. National Institutes of Health (NIH)

• Role: While not a regulatory body, the NIH supports and funds clinical trials and requires the submission of trial results and reports for its funded studies. It also maintains the ClinicalTrials.gov registry, where trial results are often posted.
• Website: NIH

4. Centers for Medicare & Medicaid Services (CMS)

• Role: For trials involving medical devices or interventions covered by Medicare or Medicaid, CMS may be involved in evaluating the effectiveness and outcomes of these interventions.
• Website: CMS

These authorities ensure that clinical trials are conducted according to regulatory standards and that the results are thoroughly reviewed and reported

Contact Us：

Whatsapp or Wechat：+86 15816864648；email address：hito.lin@grzan.cn